Literature DB >> 4357602

Differences in clinical and convalescent-phase antibodies of Rhesus monkeys infected with monkey pox, tanapox, and Yaba poxviruses.

R D Hall, R G Olsen, S P Pakes, D S Yohn.   

Abstract

Complement-fixing and complement-fixing inhibiting (CFI) antibodies were demonstrated in the clinical and convalescent stages, respectively, of rhesus monkeys infected with either monkey poxvirus, Tanapoxvirus, or Yaba poxvirus. Specificity of the CFI antibody was confirmed by its failure to cross-react with heterologous poxvirus antigens and by experiments demonstrating the CFI test as being antigen dependent. Serum containing CFI antibody neutralized homologous poxvirus but failed to agglutinate antigen-coated, tanned red blood cells. The application of CFI test as a seroepidemiologic tool for studies of poxvirus infection of man and simian monkeys and the biologic role of CFI antibody in pathogenesis were discussed.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4357602      PMCID: PMC422718          DOI: 10.1128/iai.7.4.539-546.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  IDENTIFICATION OF RABBIT, MONKEY, AND DOG ANTIBODIES WITH PCA ACTIVITY FOR GUINEA PIGS.

Authors:  Z OVARY; K J BLOCH; B BENACERRAF
Journal:  Proc Soc Exp Biol Med       Date:  1964-07

2.  Studies of lymphocytic choriomeningitis in mice. I. The relationship between age at inoculation and outcome of infection.

Authors:  J HOTCHIN; H WEIGAND
Journal:  J Immunol       Date:  1961-04       Impact factor: 5.422

3.  Direct complement fixation by turkey and chicken serum in viral systems.

Authors:  H P BRUMFIELD; B S POMEROY
Journal:  Proc Soc Exp Biol Med       Date:  1957-01

4.  An outbreak of subcutaneous tumours in rhesus monkeys.

Authors:  W G BEARCROFT; M F JAMIESON
Journal:  Nature       Date:  1958-07-19       Impact factor: 49.962

5.  Immunological determinants of avian sarcoma viruses: presence of group-specific antibodies in fowl sera demonstrated by complement-fixation inhibition test.

Authors:  G F Rabotti; E Blackham
Journal:  J Natl Cancer Inst       Date:  1970-05       Impact factor: 13.506

6.  Studies of a newly recognized poxvirus of monkeys.

Authors:  R A Crandell; H W Casey; W B Brumlow
Journal:  J Infect Dis       Date:  1969-01       Impact factor: 5.226

7.  Cellular immunity and its serum-mediated inhibition in Shope-virus-induced rabbit papillomas.

Authors:  I Hellström; C A Evans; K E Hellström
Journal:  Int J Cancer       Date:  1969-09-15       Impact factor: 7.396

8.  The complement-fixation reaction in eguine infectious anemia: demonstration of inhibition by IgG (T).

Authors:  T C McGuire; G L Van Hoosier; J B Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

9.  Simplified procedure for preparation of specific antibodies to gamma globulins.

Authors:  R G Olsen; J R McCammon; D S Yohn
Journal:  Appl Microbiol       Date:  1970-07

10.  Properties of guinea pig 7S antibodies. I. Electrophoretic separation of two types of guinea pig 7S antibodies.

Authors:  B BENACERRAF; Z OVARY; K J BLOCH; E C FRANKLIN
Journal:  J Exp Med       Date:  1963-06-01       Impact factor: 14.307

View more
  4 in total

1.  Serological evidence of infection with Tana and Yaba pox viruses among several species of monkey.

Authors:  A W Downie
Journal:  J Hyg (Lond)       Date:  1974-04

2.  Microcomplement-fixation inhibition: a rapid and economical test to detect non-complement-fixing antibodies.

Authors:  R G Olsen; L E Mathes; D S Yohn
Journal:  Appl Microbiol       Date:  1973-10

3.  Preparation and evaluation of a noninfectious monkey pox virus vaccine.

Authors:  R G Olsen; J R Blakeslee; L Mathes; J H Nakano
Journal:  J Clin Microbiol       Date:  1977-07       Impact factor: 5.948

4.  Differences in acute and convalescent-phase antibodies of cats infected with feline picornaviruses.

Authors:  R G Olsen; D E Kahn; E A Hoover; N J Saxe; D S Yohn
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.